[see in advance] selected announcement on the 20th: Hunan Zhongke Electric Co.Ltd(300035) plans to cooperate with Contemporary Amperex Technology Co.Limited(300750) to build an integrated project of lithium battery cathode materials

Hunan Zhongke Electric Co.Ltd(300035) : it is proposed to cooperate with Contemporary Amperex Technology Co.Limited(300750) to build the lithium battery cathode material integration project; Nanjing Hicin Pharmaceutical Co.Ltd(300584) : the anti covid-19 drug nimatovir API and its key intermediates project have been filed

selected Announcements:

Hunan Zhongke Electric Co.Ltd(300035) : it is proposed to cooperate with Contemporary Amperex Technology Co.Limited(300750) to build the lithium battery cathode material integration project

E company news, Hunan Zhongke Electric Co.Ltd(300035) (300035) announced on February 20 that the company and Contemporary Amperex Technology Co.Limited(300750) signed the capital increase agreement on zhongkexingcheng graphite Co., Ltd. in Gui'an new district. Zhongkexingcheng, the holding subsidiary of the company, plans to invest in the "integration project of cathode materials for lithium batteries with an annual output of 100000 tons".

Nanjing Hicin Pharmaceutical Co.Ltd(300584) : the anti covid-19 drug nimatovir API and its key intermediates project were filed

E company news, Nanjing Hicin Pharmaceutical Co.Ltd(300584) (300584) announced on February 20 that Anqing Huichen, a holding subsidiary, obtained the project record issued by the Economic Development Bureau of Anqing high tech Industrial Development Zone on February 18. The project name is "the construction project with an annual output of 100 tons of anti covid-19 drug nimatovir API and its key intermediates". The completion time of the project is 2022, and the total investment of the project is 50.08 million yuan.

Shan Dong Kexing Bioproducts Co.Ltd(688136) : cooperative development of small molecule oral drugs against covid-19 virus

E company news, Shan Dong Kexing Bioproducts Co.Ltd(688136) (688136) announced on February 20 that Shenzhen Kexing, a wholly-owned subsidiary, signed a cooperation agreement with Aetna on February 18. Globally, Aetna will exclusively license the shen26 intellectual property it has obtained or held to Shenzhen Kexing, and transfer the subsequent R & D rights and commercialization interests of products to Shenzhen Kexing. SHEN26 is an antiviral drug used for the treatment of COVID-19 and other viral infections. It has been included in the 2021 annual New Coronavirus prevention and control of New Coronavirus infection.

Dayu Water-Saving Group Co.Ltd(300021) : pre bid 385 million yuan franchise project

E company news, Dayu Water-Saving Group Co.Ltd(300021) (300021) announced on February 20 that the consortium composed of the company and its wholly-owned subsidiary is expected to win the bid for the construction franchise project of 86000 Mu irrigation project in pingtian and Wumao irrigation areas of Yuanmou County, with a total dynamic investment of 385 million yuan.

Asymchem Laboratories (Tianjin) Co.Ltd(002821) : obtained a new batch of supply contracts with an amount of about 3.542 billion yuan

E company news, Asymchem Laboratories (Tianjin) Co.Ltd(002821) (002821) announced on February 20 that in the process of continuously providing contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a pharmaceutical company (hereinafter referred to as the "customer"), Jilin Asymchem Laboratories (Tianjin) Co.Ltd(002821) , a wholly-owned subsidiary of the company, recently signed a new batch of supply contracts for related products with customers, and the contract amount is equivalent to about 3.542 billion yuan. If the contract is successfully performed and the delivery time is 2022, it is expected to have a positive impact on the company's financial situation and operating results in 2022.

Cansino Biologics Inc(688185) : the company's covid-19 vaccine was approved for sequential booster immunization

E company, Cansino Biologics Inc(688185) (688185) announced in February 20th that the company's recombinant New Coronavirus vaccine (type 5 adenovirus vector) (trade name: Ke Wei Sha) has been granted China's conditional approval and emergency use authorization in many other countries. After the product is approved for sequential immunization, if the relevant national departments increase their procurement, it will have a certain positive impact on the performance of listed companies.

Baoding Lucky Innovative Materials Co.Ltd(300446) : it is planned to purchase Aerospace Energy and aerospace molding to enter two business areas

E company news, Baoding Lucky Innovative Materials Co.Ltd(300446) (300446) announced on February 20 that it plans to issue shares to buy 100% shares of Aerospace Energy and 100% shares of aerospace molding; And plans to issue shares to raise matching funds. The valuation and pricing of the underlying assets have not been determined, and this transaction is expected to constitute a major asset restructuring. After the completion of the transaction, the company will enter the two business areas of oil and gas equipment and auto parts.

Yinyi Co.Ltd(000981) : temporary suspension of trading and conversion of capital reserve into share capital

E company news, Yinyi Co.Ltd(000981) (000981) announced on February 20 that in order to implement the conversion of capital reserve into share capital in the reorganization plan, the trading of the company's shares was suspended for four trading days from the date of equity registration (February 21) and resumed on February 25.

- Advertisment -